Published on 2/3/2022 in the Prospect News Structured Products Daily.
New Issue: UBS prices $237,500 return optimization securities on GoodRx
New York, Feb. 3 – UBS AG, London Branch priced $237,500 of return optimization securities due Jan. 25, 2023 linked to the common stock of GoodRx Holdings, Inc., according to a 424B2 filing with the Securities and Exchange Commission.
If GoodRx Holdings stock closes at or above the initial price, the payout at maturity will be par plus four times any gain in common stock of GoodRx Holdings capped at 46.2%.
Investors will share in any losses.
UBS Financial Services Inc. and UBS Investment Bank are the underwriters.
| Issuer: | UBS AG, London Branch
|
| Issue: | Return optimization securities
|
| Underlying stock: | GoodRx Holdings, Inc. (Nasdaq: GDRX)
|
| Amount: | $237,500
|
| Maturity: | Jan. 25, 2023
|
| Coupon: | 0%
|
| Price: | Par of $10
|
| Payout at maturity: | Par plus four times any gain in common stock of GoodRx Holdings, capped at 46.2%; otherwise, exposure to any losses
|
| Initial share price: | $25.04
|
| Pricing date: | Jan. 20
|
| Settlement date: | Jan. 24
|
| Underwriters: | UBS Financial Services Inc. and UBS Investment Bank
|
| Fees: | 2%
|
| Cusip: | 90302T771
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
